Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy

MicroRNAs (miRNAs), which are endogenous about 20–23 nucleotides non-coding RNAs, have been acted as post-transcriptional regulators of gene expression. Current studies demonstrated that miRNAs are promising candidates for tumor gene therapy because of their important biological functions in tumor c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hairong, Liu, Shiming, Jia, Li, Chu, Fengyun, Zhou, Ya, He, Zhixu, Guo, Mengmeng, Chen, Chao, Xu, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043968/
https://www.ncbi.nlm.nih.gov/pubmed/30008618
http://dx.doi.org/10.1186/s12935-018-0596-x
Descripción
Sumario:MicroRNAs (miRNAs), which are endogenous about 20–23 nucleotides non-coding RNAs, have been acted as post-transcriptional regulators of gene expression. Current studies demonstrated that miRNAs are promising candidates for tumor gene therapy because of their important biological functions in tumor cell proliferation, metastasis, apoptosis, and drug resistance. As an important delivery system, nanostructured lipid carriers (NLCs) have great potential in tumor gene therapy, particularly for miRNA delivery, due to low toxicity, low immunogenicity, long metabolic cycles, and easy modification. This article reviews recent research progress on NLCs for miRNA delivery in tumor gene therapy and prospective applications.

Ejemplares similares